Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$5.66 +6.0%	$3.94	$2.28 ▼ $6.90	$56.55M	0.55	107,222 shs	99,490 shs
RENB Renovaro	$0.24 +4.5%	$0.29	$0.22 ▼ $2.10	$41.14M	0.54	1.07 million shs	642,047 shs
SONN Sonnet BioTherapeutics	$3.47 +2.7%	$3.62	$1.08 ▼ $19.30	$23.44M	1.04	751,041 shs	274,504 shs
XCUR Exicure	$6.09 -1.8%	$7.05	$1.44 ▼ $36.00	$38.48M	3.67	73,592 shs	8,762 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	+56.35%	+54.64%	+138.82%	+9.69%
RENB Renovaro	0.00%	-0.04%	-26.60%	-26.87%	-63.23%
SONN Sonnet BioTherapeutics	0.00%	-1.98%	-17.77%	+207.08%	-39.34%
XCUR Exicure	0.00%	-8.42%	-25.37%	-39.34%	+1,480.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	3.2366 of 5 stars	3.6	4.0	0.0	0.0	2.1	2.5	0.6
RENB Renovaro	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	2.5767 of 5 stars	3.5	4.0	0.0	0.0	0.0	0.0	0.0
XCUR Exicure	1.8815 of 5 stars	0.0	5.0	0.0	4.7	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$33.00	483.04% Upside
RENB Renovaro	0.00	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	476.37% Upside
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SONN, CLNN, RENB, and XCUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/18/2025	CLNN Clene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$83.00 ➝ $48.00
8/14/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$340K	166.30	N/A	N/A	($0.86) per share	-6.58
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A
SONN Sonnet BioTherapeutics	$20K	1,171.13	N/A	N/A	($0.45) per share	-7.71
XCUR Exicure	$500K	76.98	N/A	N/A	$1.40 per share	4.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$3.76	N/A	N/A	N/A	-10,386.36%	N/A	-125.49%	11/12/2025 (Estimated)
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	9/29/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A
XCUR Exicure	-$9.70M	-$3.88	N/A	∞	N/A	N/A	-192.16%	-84.30%	11/12/2025 (Estimated)

Latest SONN, CLNN, RENB, and XCUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLNN Clene	-$0.49	-$0.78	-$0.29	-$0.78	$0.06 million	$0.03 million
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/8/2025	Q2 2025	XCUR Exicure	N/A	-$0.41	N/A	-$0.41	N/A	N/A
6/27/2025	Q1 2025	XCUR Exicure	N/A	-$0.45	N/A	$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.58	1.36
RENB Renovaro	N/A	0.13	0.13
SONN Sonnet BioTherapeutics	N/A	0.26	0.26
XCUR Exicure	N/A	1.89	1.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
RENB Renovaro	71.41%
SONN Sonnet BioTherapeutics	9.45%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
RENB Renovaro	0.50%
SONN Sonnet BioTherapeutics	2.00%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	9.99 million	6.46 million	Optionable
RENB Renovaro	20	172.12 million	171.26 million	Optionable
SONN Sonnet BioTherapeutics	10	6.75 million	6.62 million	Not Optionable
XCUR Exicure	50	6.32 million	6.07 million	Not Optionable

SONN, CLNN, RENB, and XCUR Headlines

Recent News About These Companies

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Drops By 51.8%

August 18, 2025 | americanbankingnews.com

Exicure Posts Wider Loss in Fiscal Q2

August 8, 2025 | aol.comA

Exicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock News

August 8, 2025 | gurufocus.com

Exicure, Inc. Reports Second Quarter 2025 Financial Results

August 8, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

August 4, 2025 | businesswire.com

Stocks to Watch: Exicure, TTEC

August 3, 2025 | marketwatch.com

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

August 1, 2025 | businesswire.com

XCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatch

July 19, 2025 | marketwatch.com

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

June 30, 2025 | msn.com

Exicure Shares Up After Swing to Profit in 1Q

June 27, 2025 | marketwatch.com

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025 | businesswire.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONN, CLNN, RENB, and XCUR Company Descriptions

Clene NASDAQ:CLNN

$5.66 +0.32 (+5.99%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.42 -0.24 (-4.22%)

As of 08/22/2025 07:58 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Renovaro NASDAQ:RENB

$0.24 +0.01 (+4.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+0.84%)

As of 08/22/2025 06:59 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Sonnet BioTherapeutics NASDAQ:SONN

$3.47 +0.09 (+2.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.50 +0.03 (+0.98%)

As of 08/22/2025 07:59 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Exicure NASDAQ:XCUR

$6.09 -0.11 (-1.77%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$6.07 -0.02 (-0.33%)

As of 08/22/2025 05:59 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time